PEB
Delivery · Highdata caveat$349M—
Pacific Edge
Oncology
Cxbladder — urine-based mRNA test for bladder cancer detection, monitoring and surveillance
Data HealthTrials4 of 4 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$349M
Burn Rate
—
Shares Outstanding
1.4B
Pipeline Assets
4
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveCapital Raise2 June 2026
PEB Completes Oversubscribed NZ$36.1m Capital Raise
$36.1MOther·at$0.170·212.4M shares
3M Price
PEB.ASX$0.255+59.4% 3M
Low $0.145High $0.255
Capital Raises & Buybacks
12mo dilution 25.2%12mo $51M3 raises
Current shares outstanding: 1.4B
Placement
Other
2026-06-03other
$36.1M
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Substantial Holders (5%+ threshold)
3 noticesarrow_drop_upHarbour Asset Management Limited
11.14%2026-05-27
arrow_drop_downHarbour Asset Management Limited
Catalysts (12)· 3 upcoming · 9 past
SpeculativeremoveMed30 May 2026
Expectedarrow_upwardHigh31 Dec 2026
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High100/100
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 6 of 6 guided dates· rolling 2yr· of 12 tracked
What drove these scores · rolling 2yr
·
Pacific Edge Launches NZ$24 Million Capital Raise — Delivered on time
·
Pacific Edge Placement Increased to NZ$25.4 Million — Delivered on time
·
Pacific Edge Opens NZ$6 Million Retail Offer — Delivered on time
·
Retail Offer Reminder — Delivered on time
·
Advancing Medicare Coverage Goals Cost Contained — Delivered on time
·
PEB Completes Oversubscribed NZ$36.1m Capital Raise — Delivered on time
Completed catalysts
✓Pacific Edge Launches NZ$24 Million Capital Raise
On time
✓Pacific Edge Placement Increased to NZ$25.4 Million
On time
✓Pacific Edge Opens NZ$6 Million Retail Offer— Pacific Edge is opening a NZ$6 million retail share offer to eligible New Zealand shareholders at NZ$0.17 per share, following a successful NZ$25.4 million institutional placement. The capital raise aims to support operations, achieve Medicare re-coverage, and fund product development and expansion in US and Asia Pacific markets.
On time
✓Retail Offer Reminder— Pacific Edge's retail capital raising offer closes 28 May 2026 with strong demand of NZ$14.0 million in applications against the target of NZ$6 million, likely requiring scaling of applications. The company is raising capital for general corporate purposes with eligible NZ-resident shareholders able to subscribe up to NZ$50,000 each.
On time
✓Advancing Medicare Coverage Goals Cost Contained— Pacific Edge achieved draft Medicare coverage (LCD DL40378) for its Cxbladder Triage and Triage Plus tests for intermediate risk microhematuria patients, expected to finalize by end of 2026. The company reported FY26 revenue of NZ$13.6M (down from NZ$24.6M due to prior Medicare coverage loss) and net loss of NZ$35.8M, but reduced monthly cash burn and secured NZ$31.4M capital raise. Draft LCD inclusion of higher-priced Triage Plus (US$1,328) represents a significant pathway to profitability.
On time
✓PEB Completes Oversubscribed NZ$36.1m Capital Raise
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(7)
4 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 1463d
CxBladder Monitor/Monitor+
Longitudinal Bladder Cancer Study for Tumour Recurrence
Urothelial Bladder Cancer
18 Years+
Primary endpoint To clinically validate the performance characteristics of CxBladder Monitor/Monitor+
ENROL450
no manual snapshots — enter via record_enrollment.py
RecruitingOBSERVATIONALEnrollment stale · 951d
Cxbladder urine test
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
Urothelial Carcinoma
18 Years – 89 Years
Primary endpoint To validate the performance characteristics of Cxbladder Triage Plus in a US cohort which will consist of subjects with a recent history of hematuria and are referred to urology and scheduled for cystoscopy for the evaluation of hematuria.
ENROL1000
no manual snapshots — enter via record_enrollment.py
NARecruitingEnrollment stale · 407d
Cxbladder Triage Plus
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Hematuria - Cause Not Known
RandomizedOpen Label18 Years – 88 Years
Primary endpoint Cystoscopy rate
ENROL1000
no manual snapshots — enter via record_enrollment.py